We know that, Axitinib (AG013736; trade name Inlyta) is a small molecule tyrosine kinase inhibitor developed by Pfizer. It has been shown to significantly inhibit growth of breast cancer in animal (xenograft) models and has shown partial responses in clinical trials with renal cell carcinoma (RCC) and several other tumour types. It was approved by the U.S. Food and Drug Administration after showing a modest increase in progression-free survival, though there have been reports of fatal adverse effects...
--------------------------------------------------------------------------------------
Now..
A Japanese single-institution study suggests that axitinib may be a
feasible first-line option for patients with locally advanced or
metastatic renal cell carcinoma (RCC). Axitinib treatment resulted in “improved oncological outcomes” and had an “acceptable safety profile”, say the researchers in BMC Urology.
The
team reviewed medical records for 18 patients with locally advanced or
metastatic RCC who received first-line axitinib for a median duration of
10.8 months, five and nine patients had a partial response and stable
disease, respectively, while four progressed.
